Generating promising biomarker signals is no longer the primary challenge – turning them into reproducible, scalable and clinically actionable tools is. This report brings together leading researchers and industry experts to explore how integrated strategies, liquid biopsies, spatial biology and artificial intelligence are reshaping biomarker science and advancing precision medicine.
How can biomarker discoveries translate into better decisions in drug development and patient care?
As biomarker science develop, the challenge is no longer solely about finding more biological signals. It is understanding which signals matter, proving they are reproducible and fit for purpose and translating them into better decisions across research and clinical development.
Our latest report explores how researchers and industry leaders are approaching this challenge – and how integrated biomarker strategies, dynamic monitoring and emerging technologies could help turn highly complex biological data into insights that can guide better decisions.
Access the report by registering for a free membership or logging into your account.
What will you learn from the report?
From discovery through to clinical development and regulation, the report explores how biomarker science is constantly changing – and what it will take to build biomarkers that can support better decisions.
Across six expert-led features, you’ll discover:
- What makes a biomarker fit for the journey from discovery to clinical development: exploring how robust approaches, workflows and technologies can help biomarkers stand up to the demands of development.
- Why integration matters: examining why the future of biomarker discovery depends on bringing technologies and biological insights together, rather than relying on individual approaches.
- How biomarkers can keep pace with tumour evolution: exploring how changing tumour biology could change biomarker strategies in precision oncology.
- How multiomics and AI are advancing next-generation cancer biomarkers: examining how these approaches can be combined to generate deeper insights into cancer biology.
- How to build better evidence for smarter drug development: exploring what is needed to strengthen the evidence base around biomarkers and support better development decisions.
- What comes next for precision medicine: examining how biomarker strategies can be strengthened from research through to regulation.
Learn from experts in biomarker science
The report features exclusive thoughts from internationally recognised researchers and industry experts, including:
- Dr Raif Yuecel, University of Exeter
- Professor Trever Bivona, University of California, San Francisco
- Professor Manos Karteris, Brunel University of London
- Gayle Marshall, Medicines Discovery Catapult
- Dr Celine Pallaud, Novartis
- Dr Amy McCann, Abcam
- Dr Florian Eich, Leica Microsystems
- Paula Villaescusa-Sanchez, Danaher.
Access the free report
Access the free report by registering for a membership or logging into your account.
Available through free Drug Target Review membership.
This report is sponsored by: Danaher
Download Now
No comments yet